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Abstract
The design of ‘hunter’ viruses aimed at destroying human immunodeficiency virus
(HIV) infected cells is an active area of research that has produced promising results
in vitro. Hunters are designed to target exposed viral envelope proteins in the
membranes of infected cells, but there is evidence that the hunter may also target
envelope proteins of free HIV, inducing virus-virus fusion. In order to predict the
effects of this fusion on therapy outcomes and determine whether fusion ability is
advantageous for hunter virus design, we have constructed a model to account for
the possibility of hunter-HIV fusion. The study was based on a target cell-limited
model of HIV infection and it examined the hunter therapeutic effect on recovering
the HIV main target cells, the activated CD4+ T lymphocytes. These cells assist in
setting up an immune response to opportunistic infections. The study analyzed the
hunter dual mechanisms to control infection and because of diverse estimates for
viral production and clearance of HIV, simulations were examined at rates spanning
an order of magnitude. Results indicate that without hunter-HIV fusion ability,
hunters that kill HIV-infected cells lead to a substantial recovery of healthy cell
population at both low and high HIV turnover rates. When hunter-HIV fusion is
included, cell recovery was particularly enhanced at lower HIV turnover rates. This
study shows that the fusion ability, in addition to hunter infection ability, could be a
favorable attribute for improving the efficacy of hunter-viral therapy. These results
provide support for the potential use of engineered viruses to control HIV and other
viral infections.
Keywords: Engineered therapeutic virus, Antiviral virus, Virus-virus fusion,
Viral dynamics, HIV super-infection, Mathematical model

Introduction
Currently, HIV-1 therapy involves long-term treatment with highly active antiretroviral
drugs (HAART). Such treatment is effective at reducing viral loads and allowing immune
system recovery, but a low level of HIV remains. This viremia may arise from latently
infected reservoirs such as resting CD4+ T-cells or sanctuary sites where drug penetration
is suboptimal [1-3]. These reservoirs have impeded the eradication of HIV [4]. A less
toxic alternative may be to control HIV through the use of another virus. Some natural
viruses have the ability to slow AIDS disease progress through mechanisms which are not
yet clear [5]. For example, infection with GB Virus C following HIV infection often slows
HIV disease progress [6]. A step further would be to design a ‘hunter’ virus that specifically targets HIV infection. Ideally, this designed virus would coexist long-term with HIV
© 2012 Greer and Garcia-Ramos; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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in the body, making multiple treatments unnecessary. Models have been proposed for the
use of an engineered defective interfering virus (DIV) as well as for a hunter virus to treat
HIV infection [7-10]. Such models may provide an important insight into the dynamics of
a hypothetical infection and elucidate the attributes of an optimal therapeutic virus.
This study builds on previous models of hunter virus super-infection [8,10]. A hunter
virus is designed to infect and kill only HIV-infected cells. Its engineered envelope contains HIV-1 host cell receptors such as CD4 and CXCR5. This allows the hunter to bind
to the HIV-1 Env proteins which are present in the membrane of HIV-1 infected cells
[11]. After binding, the hunter virus infects the cell and rapidly reproduces causing the
cell lysis. A critical feature of the therapeutic virus is that it can replicate and sustain the
therapeutic infection. Models have shown that a hunter could be very effective if
designed with high infection and production rates relative to HIV-1 [8]. Experimental
precedents exist for the creation of such a virus from a vesicular stomatitis virus (VSV)
recombinant [11,12]. Hunter virus design is still an active area of research; a highly efficient hunter virus was recently created using a similar approach to Schnell et al. [11]
but additionally incorporating human OX40 ligand in the hunter membrane [13]. These
engineered viruses were very effective in vitro, but none have yet been tested in vivo.
The model presented in this study takes some elements from previous models [8,10]
and adds an additional ability of the hunter virus to fuse with free HIV virions. Virusvirus fusion has been shown to occur between modified HIV particles or VSV and HIV
[14,15], and the resulting fused viral particles were infectious to the hosts of both component particles. Hunter-HIV fusion was also suggested with a hunter derived from
VSV [11] because of the occurrence of cells that were positive for VSV proteins but
contained undetectable levels of HIV proteins. Schnell et al. proposed that since the
hunter cannot enter a cell without the help of HIV-1 Env proteins, the two viruses may
have entered together as a fused virus, allowing the hunter to stop HIV production before it started. Thus, it is likely that a hunter virus attaches to HIV-1 Env proteins on
either infected cells or free HIV virions. In the case of hunter attachment to free HIV
virions, the resulting fused particles have membrane receptors capable of infecting either of the cell targets of the component virions: susceptible healthy CD4+ cells or
HIV-infected cells.
The model examined in the present study accounts for this possibility which has not
been considered in previous hunter models. A therapeutic virus with two targets could
significantly change the dynamics of the system and result in either increased or
decreased healthy cell recovery, making virus-virus fusion either a goal or an obstacle
in future therapeutic virus design. The purpose of this study is to use computer simulation of an infection system to evaluate activated healthy CD4+ cell recovery (and thus
therapeutic potential) in a hunter virus therapy targeted to both HIV-infected cells and
free HIV virions. The fusion between different types of viruses may have practical applications, such as in the development of a HIV vaccine [14].

Model
Model description

This study uses a target cell limited model for representing HIV infection [16], and it is
based on García-Ramos et al. (2003) [8]. HIV-1 preferentially replicates in activated
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CD4+ T cells [1,2]. A typical healthy individual has about 1000 CD4+ cells/μL in peripheral blood, but only a fraction are activated CD4+ cells and thus susceptible of HIV infection. The present model represents HIV infection and therapeutic infection using
differential equations (Eqs. 1). The equations describe the changing population densities of healthy target cells xh which are activated CD4+ cells, three types of infected
cells, and three viruses consisting of HIV-1 v, hunters w and HIV-hunter fused particles
s (see diagram in Figure 1). In this infection system, populations of cells and viruses are
impacted by various processes of birth and death. Thus, each term in a given equation
represents a process which adds or subtracts cells or virions in proportion to the rate
constant for the process and the densities of the populations participating in the
process. Rates are written in terms of production rates p, death rates of cells d, infection rates i, and removal rates of viruses r. Subscripts denote to which population a
particular parameter applies (e.g. ph refers to the production rate of healthy cells; pv:v
and pv:vw denote HIV production by xv and xvw cells, respectively). See Table 1 for a full
description of each parameter, its default value, and references. With these conventions
in mind, we can follow the events described by the equations.
The model assumes that healthy target cells xh are produced at a constant rate ph
(Eqs. 1; Figure 1). These cells are targets of infection by the population of HIV virions v.
This infection by HIV at rate iv reduces the population of healthy cells and creates
infected cells xv at a rate proportional to the populations of HIV and healthy cells. HIV
is then produced by infected cells at a rate pv:v, proportional to the infected cell

xh :
xv :
xvw :
xs :
v:
w:
s:

healthy CD4 + cells
HIV-infected
double-infected
infected by fused
HIV
hunter
fused viral particle

rss

rvv

S
rww

psvw
n

W

V
ph

Xh

pv:vxv

ivvxh

dhxh

pv:vwxvw

Xv

iwwxv + is:wsxv

pwxvw

Xvw

dvxv

dvwxvw

is:vsxh

Xs

pwxs

dsxs

Figure 1 Schematic diagram and model formulation. The elements of the model consist of cells
susceptible to viral infections (activated CD4+ cells, in large circles), HIV virions (small circles) and hunter
viruses (ovals). The diagram illustrates the dynamics of susceptible cells in healthy condition xh and the
formation of infected cell populations (HIV-infected xv and double infected xvw, xs) via pathogen or
therapeutic viral infection (HIV v, hunter w, and HIV-hunter fused particles s). Dashed arrows indicate the cell
population targeted by each type of virus. In the diagram, healthy cells xh infected by HIV are transferred to
the population of HIV-infected cells xv, and then release HIV virions. Alternatively, healthy cells xh can be
infected by fused particles s to become s-infected cells xs that release hunters. Hunters w and fused
particles s can infect HIV-infected cells and generate double-infected cells xvw, which release both HIV and
hunter virions. The graph also shows the formation of fused particles s. Parameters describe infection rates
i, death rates of cells d, removal rates of viruses r, and production rates p. Subscripts denote to which
population a particular parameter applies (see parameters in Table 1). Equations (denoted as Eqs. 1 in
Model description) describe the change in the number of cells or virions over time t (e.g. x·h = dxh/dt). The
positive and negative terms at the right side of a given equation correspond to incoming and outcoming
arrows, respectively, for the relevant population in the diagram.
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Table 1 Parameter values and initial variable values
Parameter

Healthy cell parameters

HIV related parameters

Hunter related parameters

Fused particle related parameters

Description

Value
High HIV
turnover

2

2

ph

Production rate of healthy
cell 1 (cd−1)

dh

Death rate of healthy
cell 2 (d−1)

0.01

0.01

iv

Infection rate of HIV 3 (v-1d-1)

0.004

0.004

pv:v

HIV production rate in an
HIV-infected cell 4 (vc-1d-1)

50

50×10

pv:vw

HIV production rate in a
double-infected cell † (vc-1d-1)

5

5×10

rv

Removal rate of HIV
virions 5 (d−1)

3

3×10

dv

Death rate of HIV-infected
cell 6 (d−1)

0.33

0.33

n

Constant influx of HIV 7 (vd−1)

0.84

0.84×10

iw

Infection rate of hunter 8 (v-1d-1)

0.02

0.02

9

-1 -1

pw

Production rate of hunter (vc d )

1800

1800

rw

Removal rate of hunter
virions 8 (d−1)

2

2

dvw

Death rate of a doubleinfected cell 8 (d−1)

2

2

ps

Formation rate of fused
viruses † (v-1d-1)

0.02

0.02

is:v

Infection rate of healthy
cells by s † (v-1d-1)

0.5×iv

0.5×iv

is:w

Infection rate of HIVinfected cells by s † (v-1d-1)

0.5×iw

0.5×iw

rs

Removal rate of fused
viruses † (d−1)

3

3×10

ds

Death rate of a cell first
infected with s † (d−1)

dvw

dvw

Variable
Interacting populations

Default HIV
turnover

Initial values
+

xh

Healthy CD4 cells (c)

10

xv

HIV infected cells (c)

1

xvw

Double infected cells (c)

0

xs

Cells infected by s (c)

0

v

HIV virions (v)

0.001

w

Hunter virions (v)

0.001

s

Fused virions (v)

0

Units: d, day; number of cells or virions per μL (c, v, respectively). References: 1 [8,17]; 2 [18,19]; 3 [20-22]; 4 [1,23-25]; 5
[23,26-28]; 6 [18,26,29]; 7 [30]; 8 [10]; 9 [11]; †Inferred (see Model section).

population. The therapeutic hunter virus w behaves similarly except that its target is
the HIV-infected cell population xv. Infection by hunter at rate iw creates doubleinfected cells xvw at a rate proportional to the densities of hunter viruses and HIVinfected cells. Double-infected cells then produce hunter virus at a rate pw and HIV at
a rate pv:w. Thus the hunter is capable of hijacking an HIV-infected cell to produce
more hunter viruses. Populations of cells are also diminished by inherent rates of cell
death dh, dv and dvw.
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The model presented here includes several key differences from the 2003 model [8].
The most important is the ability of free HIV and hunter to fuse at rate ps, creating a
new population of fused virions s that can infect both healthy CD4+ cells and HIVinfected cells at rates is:v and is:w, respectively. The healthy cells infected by fused viral
particles are denoted by xs, and HIV-infected cells infected by fused particles become
double-infected cells similarly to those infected by the hunter alone (xvw). The equations are described below,
x_ h ¼ ph  iv vxh  is:v sxh  dh xh
x_ v ¼ iv vxh  iw wxv  is:w sxv  dv xv
x_ vw ¼ iw wxv þ is:w sxv  dvw xvw
x_ s ¼ is:v sxh  ds xs
v_ ¼ pv:v xv þ pv:vw xvw þ n  ps vw  iv vxh  rv v
w_ ¼ pw xvw þ pw xs  ps vw  iw wxv  rw w
s_ ¼ ps vw  is:v sxh  is:w sxv  rs s

ð1Þ

The present model includes other differences from the 2003 model [8] which are summarized below: (1) The addition of a constant influx n of free HIV virions from other
sources in the body to represent a reservoir of HIV [10]. (2) The addition of a small
amount of HIV production pv:vw from cells infected by hunters [10]. (3) Cells infected by
fused virus particles xs do not produce HIV [11], and cell death occurs at rate ds. (4)
When a virus infects a cell, the model now accounts for the loss of that virus from the free
viral population. This applies to HIV, hunter, and fused viruses, therefore, the populations
of viruses are reduced via cell infection and by removal of free virions rv, rw, rs. (5) Modifications of default parameter values based on more recent estimates [10].
Thus this study differs from the 2003 model by considering the hunter’s fusion ability
as well as refining the more fundamental equations and updating parameters values. To
isolate the effect of fusion we compare the full model with a fusion-less version of itself.
Fusion can easily be removed from the model by setting the rate of production of fused
particles ps to zero. The system of differential equations was analyzed numerically using
the ode45 solver from MATLAB (version 7.14; MathWorks, Inc.).
Model evaluation

Most of the model’s parameters were either found experimentally or inferred from previous studies (see references in Table 1). However, estimates of five new default parameter values for the fused particle were required, and assumptions for inferring these
values are described below.
(1)
ps: formation rate of fused virus particles. There is no literature describing
rates of virus-virus fusion. This process requires binding of hunter to HIV-1 Env
proteins, which also occurs when the hunter infects cells. Therefore the rate was
initially assumed equal to the rate of infection by the hunter virus. Since
infection and fusion are otherwise different processes, a wide range of
production rates was tested (± 50% default value).
(2)
rs: removal rate of fused virus particles. Assumed equal to HIV-1
removal. This may be an overestimate since fusion may leave less surface area
of HIV exposed for removal mechanisms than in a free particle. Hunter
has a lower removal rate than HIV since it carries an envelope with
human proteins.
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1

1

0.1

0.1

0.01

hunter
double-infected

0

50

100

healthy cells
HIV-infected
HIV

0.01

0.01

hunter
double-infected

150

Days
100
10
1
0.1
0.01

fused particles
infected by fused

0

50

100

150

Days
Figure 2 Infection dynamics for both types of hunters. (A) Hunter virus only targets HIV-infected cells
(updated 2003 model). (B) Hunter virus double targeted (fusion model). First 150 days after hunter
introductions. Healthy CD4+ cell count in both models continues to increase until reaching equilibrium by
day 400 in the updated 2003 model and a limit cycle of negligible amplitude by day 700 in the fusion
model. In the fusion model, the other populations also show cyclic behaviors. For exact densities, see
Table 2. Values of the parameters are in Table 1.

(3)
ds: death rate of a previously healthy cell infected by s. Assumed equal to death
rate of double-infected cells by default. However, the life cycle of these cells may differ
because HIV may have not altered the cell's structure or function. Perhaps this causes
a change in the speed that a hunter can replicate and kill the cell. Therefore, a range
of values was tested.
(4–5) is:v and is:w: infection rate of healthy cells and HIV-infected cells by fused
particles, respectively (see illustration of hunter-HIV fusion in Additional file 1). We
assumed that this fused particle has a fraction of receptors for each viral component
Table 2 Equilibrium densities for the populations of cells and virions
Default parameters (Low HIV turnover)

High HIV turnover

No fusion

Fusiona

No fusion

Fusion

98 (49%)

141.8-142.2 (71%)

91 (45.5%)

104 (52%)

HIV-infected cells

0.11

0.03-0.12

0.11

0.1

HIV

2.6

0.31-1.0

3

2

Healthy cells (% Recovery)

Hunter

443

180-340

472

408

Double-infected cells

0.49

0.09-0.25

0.52

0.41

Fused virus particles s

–

0.52-1.4

–

0.55

Infected by fused s

–

0.08-0.17

–

0.06

Interval values for stable oscillations obtained at about 700 days. Units: counts of cells or viruses per μL.

a
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available for cell infection. Therefore, default was assumed to be lower than the
infection rate by single particles.
To evaluate the model, we first determined the percentage of recovery of healthy cells
for the default parameter values (Figure 2, Table 2). Because parameter estimates for
the therapeutic infection rely on inference rather than experimental data, we performed
sensitivity analyses that estimated cell recovery when each of the parameters in the
model was subjected to a ± 50% change in value (Table 3). We then examined the effect

Table 3 Parameter sensitivities
Parameter

Parameter change
from default ± 50%

% Recovery of healthy
cells at low HIV turnover

% Recovery of healthy
cells at high HIV turnover

Default

0

71

52

iv

+

61

42

–

80

69

pv:v

+

62

45

–

78

63

pv:vw

+

71

49

–

70

55

rv

+

74

61

–

67

40

dv

+

72

52

–

71

52

n

+

71

51

–

68

53

iw

+

76 (+5)

58 (+6)

–

55

37

pw

+

79 (+8)

61 (+9)

–

47

35

rw

+

59

43

–

83 (+12)

66 (+14)

dvw

+

64

44

–

77 (+6)

57 (+5)

ps

+

74 (+3)

54 (+2)

–

66

49

is:v

+

71

52

–

71

52

is:w

+

71

52

–

71

52

rs

+

70

52

–

71

52

ds

+

66

51

–

79 (+8)

55 (+3)

The percent of healthy CD4+ cell recovery caused by changing model parameters values at low (default) and high
(10×default) HIV turnover values. Results were similar for different initial values of the variables. Note: The parameters ph
and dh were not tested for sensitivity because they define the base healthy CD4+ cell concentration of 200 cells/μL to
which all other results are compared. Parenthesis indicates the additional recovery in relation to default for hunter
related parameters.
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Table 4 Sensitivity of CD4+ cell recovery to infection rates of fused particles s
Infection rates (μL/virion day)

is:v = iv

is:v = 0.5×iv

is:v = 0

is:v = 0

is:v = 0.5×iv

is:w = iw

is:w = 0.5×iw *

is:w = 0

is:w = 0.5×iw

is:w = 0

Healthy cells at default HIV turnover
(cells/μL)

142 (71%)

142 (71%)

139 (70%)

142 (71%)

139 (70%)

Healthy cells at high HIV turnover
(cells/μL)

104 (52%)

104 (52%)

104 (52%)

104 (52%)

104 (52%)

*: default.
Note: Percentage indicates the recovery relative to the maximum healthy level.

of simultaneously manipulating both cell infection rates by fused particles s (Table 4);
as well as the concerted effects of fused particle formation and hunter infection rates
on cell recovery (Figure 3). In addition, these analyses were also assessed for the overall
effect of HIV turnover rates on the hunter therapeutic efficacy (Table 2; Figure 4).

Results
Without HIV infection, the model predicts a maximum density of susceptible healthy
cells that we referenced as 100% healthy cell level. This maximum density was 200
cells/μL, and this particular value agrees with previous infection models based on activated CD4+ cells [16,20]. Because activated cells are a fraction of the CD4+ cell population, we discuss the results in terms of percent healthy level rather than cell density.
With HIV infection only, healthy cell density at equilibrium is reduced to 2.5% of the
healthy level ( ^x h ¼ 5 cells=μL ). In order to assess the effect of hunter fusion, results
were obtained for a hunter that targeted only HIV-infected cells as well as for a hunter
that targeted both HIV-infected cells and free HIV virions. Because different techniques
have yielded a variety of estimates for viral production and clearance of HIV [23,26,27],
the same simulations were run at lower and higher rates of HIV turnover. A summary
of these results and a full list of population densities at equilibrium for each scenario
are included in Table 2.
When the hunter virus targeted HIV-infected cells only, the healthy cell population
recovers to 49% of the normal level ( ^x h ¼ 98 cells=μL ). When the hunter also
fused to free HIV virions, the healthy cell population recovered to 71% of the normal
level ( ^x h ¼ 142 cells=μL ). Thus, the targeting of free HIV by the hunter significantly
improves the effectiveness of therapy at default parameter values. The two scenarios
showed distinctive behaviors consisting of equilibrium (without fusion) and limit cycles
(with fusion), which were reached at different speeds but the general dynamic is clearly
seen within the first 150 days (Figures 2A, B). In a limit cycle, a variable continuously
changes value through time but returns to the same value at fixed time intervals. In the
fusion model, the healthy cell population exhibited a limit cycle with negligible amplitude of oscillation, while the other populations continued to oscillate at larger amplitudes. Despite these oscillations the free HIV concentration stayed well below that of
the model without fusion. Simulations were run for several initial conditions besides
those in Table 1, and the system reached the same equilibrium (without fusion) or limit
cycles (with fusion; Figures 2A, B), suggesting that the dynamics were globally stable.
The appearance of oscillatory dynamics reflects the larger HIV control by a default
hunter with fusion ability. Notice that the dynamical behavior in the fusion model may
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0.04
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0.03
70 %

0.02
60 %

*

50 %

0.01 40 %

0.04
60 %

0.03
50 %

0.02

*
40 %

0.01
0

0.01

0.02

0.03

0.04

Fused particle formation rate
(1/(virions/µL)d)
Figure 3 Influence of hunter infection rate and fused particle fusion rate on therapeutic efficacy.
Each line represents the combinations of hunter infection and fused particle formation rates which yield a
particular percent of cell recovery. (A) At default HIV turnover rate. Raising hunter infection rate alone
increases recovery faster than raising fused particle production rate alone, but optimal recovery is achieved
by increasing both parameters. Recovery increases steeply at lower values and then begins to level off.
(B) At high HIV turnover rate (10×default). Fusion rate has very little influence on recovery at low hunter
infection rates, but the therapeutic benefit of hunter-HIV fusion improves greatly at high hunter infection
rates. The asterisk (*) represents cell recovery at the default combination of parameter values (Table 1).

change with values of the parameters. For example at high HIV turnover rate values
(Table 1) the fusion model showed equilibrium instead of limit cycles (Table 2).
Estimates of HIV production and removal rates can be greater than the default values
[24,27,28]. Therefore, the simulation was run at default rates as well as at a range of
HIV production and removal rates up to ten times greater than default (Figures 3A, B
and 4). This required raising HIV production pv:v in infected cells, production pv:vw in
double-infected cells, influx rate n, HIV virus removal rv, and fused virus removal rs
(Table 1). The effectiveness of the hunter virus decreased as HIV turnover increased,
but the hunter had a significant therapeutic effect even at the highest turnover rates
(Figure 4). The decrease in recovery with HIV turnover was much steeper in the fusion
model. At ten times default HIV production and removal rates, cells recovered to 46%
( ^x h ¼ 91 cells=μL ) without fusion vs. cells recovered to 52% ( ^x h ¼ 104 cells=μL ) of

Healthy cell recovery (%)
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with fusion
without fusion

75

50

25

0

1

4
7
HIV turnover factor

10

Figure 4 Effect of HIV turnover rate on therapy efficiency. Recovery decreases as HIV turnover rate
increases. The decrease is steeper for a fusion-capable hunter, decreasing (but not eliminating) its
advantage over fusion-incapable hunter at high turnover rates. Within this range, the fusion model displays
periodic oscillations at lower HIV turnover rates (<1.7× default). Otherwise, the models reach a stable
equilibrium.

normal levels with fusion. Thus at larger rate of HIV turnover, fusion ability confers a
smaller advantage to the hunter.

Model sensitivity

An analytical solution to the equilibrium equations could not be found, but a virtual
experiment provided insight into the driving force behind the improved recovery of
healthy cells in the fusion model. The therapeutic infection was run for different parameter values (± 50% each default value) and results show that recovery was insensitive
to fused particle infection rates is:v and is:w, and to removal rate rs (Table 3). In our previous study [8], the infection rate of the hunter iw was a critical factor for successful
hunter virus treatment, and it is important in this study as well. Variation in HIV infection rate iv and hunter removal rate rw also significantly altered the resulting recovery.
The production rate ps of fused particles and the death rate ds of cells infected by fused
virus particles are the most sensitive of the new fusion-related parameters introduced
in this study.

Sensitivity due to fused particle structure: alternative infection rates

A fused particle contains the envelope proteins of both HIV and hunter, so it could potentially infect either healthy cells or HIV-infected cells. The mechanism of fusion and
the structure of the resulting particle are unknown, but the model at default parameters
assumes that the fused particle envelope maintains spatially separate regions for the envelope proteins of its composite viruses. A simple representation of a fused particle is
shown in Figure S1 and it drawn to scale using established dimensions of the spherical
HIV virion and cylindrical VSV virion [31,32]. Briefly, the model at default parameter
values assumes that each particle has half of its receptors available for binding and
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infecting its target cell while the other half are blocked by the other virion. Thus the infection rate is:v of the fused particle in healthy cells is half of the HIV infection rate iv.
Likewise the infection rate is:w of HIV-infected cells is half of the hunter infection rate
iw. It is also possible that the viruses merge and change conformation, which could lead
to uneven ratios of available receptors and thus infection rates. Therefore, the model
was also tested in the extreme scenarios. Surprisingly, recovery was unaffected even
when the infective ability of fused virus particles was completely removed from the
model. This was observed both at default parameter values and with rapid HIV turnover rates (Table 4).
Formation of multiple fused particles: an alternative model

Models were also created to include the formation of other combinations of fused virus
particles (see Additional file 1). Since each HIV virion has several protein spikes capable
of binding to CD4 and coreceptors [32], it is possible that more than one hunter might
bind to the same HIV particle. Likewise, each hunter has several CD4 molecules in its
membrane, so it could bind to multiple HIV [11]. Accounting for these possibilities did
not significantly affect cell recovery.
Accounting for defective HIV particles

Since only a fraction of HIV particles produced is infectious, we modified the model to
account for the defective HIV particles that may fuse with the hunter and restrict it
from reaching its target (see Additional file 1). We assumed that 10% of HIV particles
released is infectious [25]. Surprisingly, healthy cell recovery was unaffected in this scenario. The hunter population remains large enough to effectively control the HIV load.

Discussion and conclusions
How exactly does the ability of the hunter virus fusion with free HIV result in
improved healthy cell recovery? Hunter-HIV fusion may facilitate recovery through
both the formation of the fused particle, as well as the ability of the fused particle to infect healthy and HIV-infected cells. Our results indicated that the fused particle’s infection rates proved to have little effect on cell recovery (Table 4). This suggests that the
infection of healthy cells by fused particles, which offer an additional and large source
of hunters, may be canceled because of the cost of killing these healthy cells. Even
though fused particles can kill HIV-infected cells and further reduce HIV load, these
outcomes insignificantly affected the recovery of healthy cells under the range of the infection rates tested (Table 4). Enhanced recovery then must result from the fusion
process itself, which reduces free HIV load. When HIV fuses with hunter, HIV is no
longer able to complete its production/life cycle. Even though HIV can still infect
healthy cells, these cells are not releasing HIV virions. Though hunter-HIV fusion
caused some loss of hunters, this did not appear to significantly affect hunter density
since it was much larger than HIV (Table 2).
Results of this study indicate that hunter virus therapy could be very effective against
HIV, especially when the hunter is capable of fusing with free HIV particles. When the
hunter was capable of fusion, the model yielded healthy CD4+ cell recovery to 71% of
normal levels, compared to a 49% recovery in treatment without fusion ability (Table 2).
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Thus the ability of a hunter to fuse with both target cells and free virus significantly
enhances (by 45%) therapeutic outcome when the default parameters were used. The
extent of recovery varied under other sets of parameters, with a minimum of 52% recovery seen in simulations with HIV production and removal rates raised by an order
of magnitude (Table 2). In all cases tested, however, recovery was better with fusion
ability than without (Figures 3A, B and 4, Table 2). Accounting for other possibilities
such as multiple fusion events and fusion with non-infectious free HIV did not greatly
affect recovery (see Additional file 1).
Which parameter values deserve the attention of a virus designer? As listed in the
‘Parameter estimations’ section of this study, five new parameters were introduced. Decreasing either the death rate ds of cells infected by fused particles or the death rate dvw
of double-infected cells improves recovery (i.e. a longer life of these cells would produce more hunters, Table 3). The hunter infection rate iw, is a critical parameter and
was examined extensively in this study (Figure 3). Without a high hunter infection rate,
a higher proliferation rate of the hunters would be required to achieve a significant recovery of the healthy cell population. The most efficient path to recovery appears to be
at ratios in which the infection rate of the hunter is slightly higher than the production
rate of fused particles (Figure 3). Therefore of the new parameters related to fusion, the
death rate ds and the formation rate ps of fused particles are for virus designers the
most useful and modifiable parameters. Given the broad range of estimates for HIV
production and clearance rates, it is important to determine to what extent cell recovery via hunter–HIV fusion depends on these turnover rates. Previous studies found that
HIV turnover rate had little effect on the hunter efficiency of killing HIV-infected cells,
while larger estimates of HIV clearance tended to cancel larger HIV production resulting in a similar recovery [8,10]. In the present study, a range of HIV production and removal rates spanning an order of magnitude was examined [23,24,27,28]. The overall
therapeutic effect decreased as these rates increased, but in all cases recovery was
therapeutically significant, and fusion ability conferred an advantage to the hunter virus
(Figure 4). Thus the model suggests that hunter virus treatment may offer significant
therapeutic benefit even at very high rates of HIV turnover, and treatment is further
enhanced when the hunter virus can also fuse to its target free virion.
Admittedly there are several processes left unaccounted for by this model, the most
significant of which are the immune response and cell dynamics [10], and the spatial
distribution of viruses and cells within the body [33]. However, the exact mechanism of
T-cell depletion is still under scrutiny, as is the rate of viral exchange between body
compartments [23,34]. In a previous study we evaluated the original hunter in the presence of a target cell life cycle with resting and activated stages along a CTL (cytotoxic
T-lymphocyte) immune response [10]. CTL is considered the main immune response
against HIV infection via killing infected cells. Therapy efficacy with these refinements
[10] was consistent with findings in the 2003 model based on activated CD4+ cells and
with no CTL [8]. The present model sought to avoid a complex system in favor of simplicity and extrapolation. It can be extrapolated that fusion ability could further aid recovery in the presence of an immune response by creating a state of lowered free HIV
density, which has been correlated with reduced apoptosis of healthy cells and reduced
overall immune activation [35,36]. On the other hand, the CTL immune response was
shown to compete with the hunter virus for HIV-infected cells, and the less efficient
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competitor was eliminated [10], indicating that this immune response did not persist
with effective hunters. This suggests that the present model could be capable of capturing the expected levels of cell recovery without modeling a complex immune response.
Also, it is possible that the hunter may have the added benefit of targeting latently
infected CD4+ cells and significantly reducing the HIV reservoir; however, we suspect
that this additional dynamic would not change qualitatively our results.
When considering the results of this study with the 2003 study, the most influential
parameters in hunter virus design include: (1) the infection rate of the hunter virus and
(2) the formation rate of fused HIV-hunter particles. These processes are comparable
to CTL and antibody immune responses, respectively. In this study which featured a
low population of infected cells and HIV virions (typical of a chronic HIV infection),
the hunter infection rate had a greater effect than fusion rate, and the best results are
obtained by a combination of infection and fusion ability (Figure 3). Thus, an ideal
hunter virus should both infect and fuse at the highest possible rates. Further in vitro
testing of the hunter virus will help to quantify the HIV-hunter fusion rate more precisely and identify the attributes determining fusion rate so that this knowledge can be
applied in future hunter virus design. Also, in vivo testing of the hunter virus could
allow an assessment of this model’s prediction regarding effectiveness thresholds for
the hunter virus and therapeutic value in the presence of an immune response.
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